THE IMPACT OF EARLY TREATMENT WITH ADALIMUMAB ON RHEUMATOID FACTOR AND ANTI-CITRULLINATED PEPTIDE ANTIBODY LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE OPTIMA TRIAL

被引：1
|
作者：
Smolen, J. S. [1 ]
Kavanaugh, A. [2 ]
Aletaha, D. [1 ]
Florentinus, S. [3 ]
Li, Y. [3 ]
Lagunes, I. [3 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Univ Calif San Diego, San Diego, CA 92103 USA
[3] AbbVie, N Chicago, IL USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.1311
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0135
引用
收藏
页码：229 / 230
页数：2
相关论文
共 50 条
  • [1] Decrease in rheumatoid factor and anti-citrullinated protein antibody levels is associated with response to adalimumab treatment in patients with rheumatoid arthritis
    Bos, Wouter H.
    Bartelds, Geertje M.
    de Koning, Margret H. M. T.
    Wolbink, Gerrit Jan
    van de Stadt, Rob J.
    van Schaardenburg, Dirkjan
    Dijkmans, Ben A. C.
    Nurmohamed, Michael T.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S542 - S543
  • [2] Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis
    Wanruchada Katchamart
    Ajchara Koolvisoot
    Emvalee Aromdee
    Praveena Chiowchanwesawakit
    Chayawee Muengchan
    Rheumatology International, 2015, 35 : 1693 - 1699
  • [3] Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis
    Katchamart, Wanruchada
    Koolvisoot, Ajchara
    Aromdee, Emvalee
    Chiowchanwesawakit, Praveena
    Muengchan, Chayawee
    RHEUMATOLOGY INTERNATIONAL, 2015, 35 (10) : 1693 - 1699
  • [4] Impact of Anti-Citrullinated Protein Antibody and/or Rheumatoid Factor on Rheumatoid Arthritis Manifestations and Outcomes
    Koh, Ee Tzun
    Chan, Angela Marie
    See, Wei Qiang
    Xiang, Wenwei
    Leong, Khai Pang
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [5] Anti-citrullinated peptide antibody: death of the rheumatoid factor?
    Chatfield, Simon M.
    Wicks, Ian P.
    Sturgess, Allan D.
    Roberts, Lynden J.
    MEDICAL JOURNAL OF AUSTRALIA, 2009, 190 (12) : 693 - 695
  • [6] THE VALUE OF ANTI-CITRULLINATED PEPTIDE ANTIBODY IN THE DIAGNOSIS OF RHEUMATOID ARTHRITIS
    Doherty, Teresa
    Martin, Keith
    Ruth, Chen
    Panthakalam, Sathianathan
    RHEUMATOLOGY, 2010, 49 : I132 - I133
  • [7] The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis
    van Jaarsveld, CHM
    ter Borg, EJ
    Jacobs, JWG
    Schellekens, GA
    Gmelig-Meyling, FHJ
    van Booma-Frankfort, C
    de Jong, BAW
    van Venrooij, WJ
    Bijlsma, JWJ
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1999, 17 (06) : 689 - 697
  • [8] Effect on rheumatoid factor and anti-Cyclic Citrullinated Peptide Antibodies Levels of treatment with Infliximab and Adalimumab in patients with Rheumatoid Arthritis
    Baos, Selene
    Plasencia, Chamaida
    Ramiro, Susana
    Moral, Rosario
    Diez, Jesus
    Martin-Mola, E.
    Balsa, Alejandro
    Pascual-Salcedo, Dora
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S489 - S489
  • [9] Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis
    Ahmed, M. Mubashir
    Mubashir, Eisha
    Wolf, Robert E.
    Hayat, Samina
    Hall, Vicky
    Shi, Runhua
    Berney, Seth Mark
    SOUTHERN MEDICAL JOURNAL, 2006, 99 (11) : 1209 - 1215
  • [10] Disease characteristics in high versus low titers of rheumatoid factor or anti-citrullinated peptide antibody in rheumatoid arthritis patients
    Sobhy, Nesreen
    Ghoniem, Shada A.
    Eissa, Basma M.
    Kamal, Asmaa
    Medhat, Amira
    Elsaid, Nora Y.
    EGYPTIAN RHEUMATOLOGIST, 2022, 44 (04): : 325 - 328
12345